## IHE-RO Technical Committee Face-to-Face Sep 27-29, 2015 at 8:30-5:30, Sep 30 8:30-12:00 ET Melbourne Fl, @ Sun Nuclear

## Technical Committee Chairs: Scott Hadley, PhD Chris Pauer, Accuray

# IHERO Task Force Co-Chairs Dick Fraass, Ph.D., FAAPM, FASTRO, FACR John Buatti, MD

15 Mission Statement: The American Society for Radiology Oncology (ASTRO) has formed a multi-society Task Force to undertake an initiative to promote the Integration of the Healthcare Enterprise (IHE) – Radiation Oncology (RO), fostering seamless connectivity and integration of radiotherapy equipment and the patient health information systems. The Task Force will include members from ASTRO, RSNA, American Association of Physicists in Medicine (AAPM), the American College of Radiology (ACR) and the Medical Imaging and Technology Alliance (MITA). In addition, members of the International community have also been invited to participate in IHE-RO. The IHE-RO Task Force, in

close collaboration with radiotherapy product manufacturers, will develop appropriate integration profiles for radiation therapy and setup a demonstration of seamless communication among the full array of radiotherapy products.

#### 25

### Attendees:

Name	Affiliation	Email	9/27/15	9/28/15	9/29/15	9/30/15
Chris Pauer	Accuray	cpauer@accuray.com	Х	Х	Х	Х
Scott Hadley	UMich	swhadley@med.umich.edu	Х	Х	Х	Х
Walter Bosch	Wash. Univ.	bosch@wustl.edu	Х	Х	Х	Х
Uli Busch	Varian	Ulrich.busch@varian.com	Х	Х	Х	Х
Koua Yang	Philips	koua.yang@philips.com	Х	Х	Х	Х
Sven Siekmann	Brainlab	Sven.siekmann@brainlab.com	Х	Х	Х	Х
Rickard Holmberg	RaySearch	Rickard.holmberg@raysearchlabs.com	Х	Х	Х	Х
Mikael Bertze	RaySearch	mikael.bertze@raysearchlabs.com	Х	Х	Х	Х
Jim Percy	Elekta	Jim.percy@elekta.com	Х	Х	Х	Х
Wouter Vreeman	ICT	wouter.vreeman@ict.nl		W		
Marco Kemper	ICT	Marco.kemper@ict.nl		W		
Bridget Koontz	Duke Univ.	bridget.koontz@duke.edu			W	
Adam Earwicker	Varian	adam.earwicker@varian.com			W	
Crystal Carter	ASTRO	Crystal.Carter@astro.org			W	
Shannon Regan	ASTRO	Shannon.Regan@astro.org			W	

X = In person W = via Webex ()

# 30

# Minutes:

- I. Call to Order (Sept. 27, 2015 at 9:00 am EDT) a quorum was declared.
  - a. Review Agenda
  - b. Other broad topics to add Updated agenda was approved without objections.

10

35

		с.	Minutes from la	ast meetings s of July, Aug TC teleconferences are on ihe-ro.org for review and approval on 9/28.
40		d. e.		For ICT – Sprint update on Tuesday (time TBA)
	TT	D ·		
	11.	Business a.	Topic 1: Level	Set
		u.	-	s on IHE-RO activities
45			1.	Planning, Oversight, Steering Committees – Chris updated the TC on activities of the
				IHE-RO PC and steering committee.
				Other Updates – Discussion of changes in IHE membership pricing structure.
			-	eleconferences An IHE-RO group was created to work on RO-HIS issues, but has not yet begun
50			1.	work.
			2.	IHE has a joint workgroup to address IHE HL7 issues (see
				http://wiki.ihe.net/index.php?title=IHE-HL7 Joint Workgroup)
			3.	What is missing? Someone interested. Vendor Product possibility. Prioritization from
55			4	customer Possible drivers? Regulatory pressure. Product possibility (MyChart, Healthshare
55			4.	Patient Community RO)
		b.	Topic 3: Review	w of Material presented to Planning Committee
				ents for the following proposed Use Cases are available at
<u>(</u> )				viki.ihe.net/index.php?title=Radiation_Oncology#Use_Cases_Being_Developed_into_I
60				ion_Profiles s what was presented, what needs to change (listed in order of scores)
			1. Discuss	<b>Treatment Delivery Device Integration</b> – covered by TDPC, TDIC, treatment
				delivery workflow profiles.
				a. What additional common workflows in the RT clinic are not covered by the
65				existing Profiles? E.g., patient QA.
			2	b. Treatment Record consistent content is not yet addressed <b>Padiation Operatory Workford Evaluation with UIS (POWE)</b> Score <sup>2</sup> (CPRO is a
			2.	<b>Radiation Oncology Workflow Exchange with HIS (ROWE)</b> – Scope? CPRO is a start, but addresses only patient identification. See IHE-ITI Patient Information
				Reconciliation (PIR) Profile. A working relationship with HIS manufacturer(s) and
70				HL7 expertise is needed.
				a. More detailed information regarding the scope of this Use Case is needed.
			3.	<b>User Case Anonymization</b> – See IHE-ITI Anonymization Handbook. The IHE-RAD
				TF1 Teaching File and Clinical Trials Export (TCE) Profile may be good a starting point.
75				a. To what extent is this an interoperability problem?
				b. What is the deliverable? RO-TCE Profile? RO-specific anonymization
				handbook?
				c. Are there Rad Onc specific considerations?
80			4	d. What are the legal and regulatory requirements? HIPAA? IRB? <b>Brachytherapy</b> – DICOM standard (1 <sup>st</sup> gen) is in place – a Brachytherapy Profile is in
80			4.	development in DICOM Brachy Sub-group
				a. A workflow profile is needed for brachytherapy treatment delivery.
			5.	Authentication / Authorization – See IHE-ITI Enterprise User Authentication
o <b>-</b>				(EUA) and Cross-Enterprise User Assertion (XUA) Profiles as a starting point.
85				a. Is any additional profile development required?
			6	b. Any Rad Onc specific issues? Survivorship Care Plan – communicate ASTRO Survivorship Care Plan Template to
			0.	TMS. Gather, store, communicate patient care information from TMS and EHR for
				follow-up care of RT.
90				a. What is the workflow to gather these data?
				b. Where are the data stored?
				c. How are they to be communicated?

95	7.	<ul> <li>d. Where are they to be reviewed?</li> <li>Off-line Review 3rd Party Imaging – Image content is addressed by TPIC, TDIC.</li> <li>Workflow is addressed by IPDW, DPDW.</li> <li>a. Existing imaging applications do not completely and consistently implement DICOM.</li> </ul>
	8.	<b>Decubitus Patient Positioning in RT Workflow</b> – Could be handled as an Option in BRTO-II (require consistent handling of patient geometry and labeling).
100		Dielo in (require consistent nationing of parton geometry and mooring).
	[Lunch break 9/27, 12:30-1:30p	em]
		D, MITA, ROSSI – no update at this time A update presented by Uli
105	1.	2 <sup>nd</sup> Gen RT is top priority
	2.	Sup 185 (Content Assessment Result IOD) has been published for Public Comment through Nov 2, 2015. Expected to be approved for Letter Ballot at the Nov WG-06 meeting.
110	3.	Sup 184 (Brachy Application Setup Delivery Instruction IOD) is now in Letter Ballot through Nov 2.
		CP 1504 (Accessory Coding) to be discussed with respect to TDPC.
115	6. 7.	CP 1516 (Adds data to the Person or Device Macro) is referenced in QAPV Profile. CP 1488 (Exposure data in RT Image) to be discussed with respect to TDIC. CP 1502 (Pixel Intensity Relationship) addresses issues in TDIC and TPIC.
115	8.	<ul> <li>ROI Template is to be developed as a DICOM IOD or SR template.</li> <li>9. Sup 147 – Approval is anticipated for trial implementation in Nov 2015. Some concerns persist in WG-06 that trial implementations may continue into production versions. Vendors should plan to being development of trial implementations in 2016.</li> </ul>
120		<ol> <li>Sup 175 (Radiations) and 176 (Non-C-arm Radiations) are expected to be through Public Comment by the second half of 2016. Sup 177 (Dose) by the end of 2016.</li> <li>Radiation Dose Structured Report (RDSR) – the current RDSR does not work for CBCT. The IHE-RAD REM (Radiation Exposure Monitoring) profile is also not</li> </ol>
		appropriate. A Patient RDSR (Sup 191) is in development.
125	12.	A Planning Record IOD (companion object) is in development to capture information
	v. NEMA	treatment planning meta-information.
		The RT2 (Safety Standard with FDA) and RT3 (Machine Characterization) are being
130		developed under the AAMI (Association for the Advancement of Medical Instrumentation).
150	2.	These efforts will continue under AdvaMed (contact is Ruey Dempsey, V. Pres of
		Technology and Regulatory Affairs).
		Survey Results – Scott reviewed results of the Prescription Survey
135	1. Summa	ary points from survey results Overall radiation oncology clinics include many of the same items in their treatment
100		prescription.
		• 90% and above reported they include total dose, technique, number of fractions,
	•	fractions per week, and dose per fraction The majority of prescription items are entered in the prescription by radiation
140		oncologsts
110		<ul> <li>100% reported that organ at risk and motion management strategy were entered by the radiation oncologists</li> </ul>
	•	Nine out of fifteen prescription items were reported to be used by therapists 100% of the time

145		<ul> <li>This includes technique, prescription coverage goals, normalization isodose surface, motion management strategy, mode, fractions per week, dose per fractions, bolus and beam energy</li> </ul>
		<ul> <li>Majority of individuals reported they have a separate treatment planning directive or</li> </ul>
		place to communicate planning goals
150		<ul> <li>Respondents mostly reported they have a separate form where they are able to fill out the treatment goals</li> </ul>
155		<ul> <li>Discussion of variations in prescription workflow, what actors are involved, minimum requirements for display of information by consumers. Different consumers may need to display different subsets of the prescription, but all information must be preserved.</li> </ul>
	[Adjourn for the [Resume on 9/2]	ae day 9/27 at 5:00pm] 28 at 8:50am]
160	d.	Topic 5.5: DICOM Content Template – Uli reviewed reorganization of DICOM Content specification in Volume III, Chapter 7 used to organize attribute requirements as a library. This approach will bring together IHE-RO usage requirements for DICOM IODs and Modules in one place and will replace attribute requirements in Integration Profile text by references to IOD sections in Chapter 7. The IOD sections in Chapter 7.3 identify required Modules and reference the appropriate Module Sections in
165		<ul> <li>7.4. Module sections contain attribute usage requirements for a specific context or clinical state.</li> <li>i. Chapter 7 material does not reference specific Integration Profiles. Instead, usage context and roles are abstracted and the abstract categories are referenced in Transaction requirements in Volume II.</li> </ul>
170		<ul> <li>ii. DICOM Content Template sections are being prepared for use in BRTO-II, TPPC, TPIC, TDPC, TDIC, TDW-II, CDEB, Brachy, and QAPV (to be re-formatted) Profiles.</li> <li>iii. Organization of Module definitions and maintenance of Chapter 7 was discussed. Variations in attribute requirements per usage category could be maintained with each item of the Module table or by adding new tables to override requirements in a particular context.</li> <li>iv. A list of Chapter 7 Sections is maintained on the Profile page of the ihe-ro.org wiki.</li> </ul>
175	e.	Update from Mary Jungers 9/28/15 – The TPPC, TPIC, TDPC, TDIC profiles are expected to be released for public comment next week.
180	f.	<ul> <li>Topic 10: DPDW update</li> <li>i. The DPDW working group reported progress from their summer meeting in Malaga in June 2015. Approximately 30 Transactions have been identified.</li> <li>ii. DICOM Sup 160 Patient Positioning and Workflow is in development.</li> </ul>
		<ul> <li>iii. Several outstanding issues remain.</li> <li>1. The scoping/granularity of instructions and number of instructions (procedure steps) are being discussed.</li> <li>2. How to establish subscription to UPS service – may require definition of some new</li> </ul>
185		<ol> <li>now to establish subscription to CFS service - may require definition of some new services, e.g., a per-station subscription service.</li> <li>An interrupt/suspended state is needed.</li> </ol>
100	g.	Topic 13: ICT Update – Wouter Vreeman, Martin i. Update on the last 4 months
190		<ol> <li>Resolved Connectathon issues 40-46, release of updated profiles</li> <li>Implemented changes for MMRO-III, update MMRO-II test tool to use user-defined datasets</li> <li>Dataset check tool, check option to start scenario from command line with parameter,</li> </ol>
195		<ul> <li>UPS server bug fix</li> <li>ii. Planning up to the end of contract (Feb 2016) was reviewed</li> <li>iii. Sprint 19 overview – ended 9/25/15</li> <li>iv. Sprint 19 results</li> <li>v. Issue list</li> </ul>

		1. MMRO-II data incorrectly coded
200		2. MMRO-II archive scenario incorrectly requires patient position for REG
		3. BRTO structure set image reference incorrectly requires contours on every slice
	vi.	Sprint 20 plans
		Demo of dataset check tool
		Media Validator Test Tools
205		1. Make it easy to add/adjust content check rules
200		2. Use Excel as intermediate format content validation rules and IHE-RO test tool
		documentation
		3. On-the-fly addition of new content validation rules to a media validator application
010		4. Initial support for TPPC, TPIC, TDPC, TDIC
210		5. Data flow: .Doc files $\rightarrow$ .csv files (module/rules, IOD tables) $\rightarrow$ module tables/rules,
		VB.net code
		6. Uses existing DICOM definition files and extends by applying additional Visual Basic
		rules.
	ix.	Feedback/Questions
215		1. Marco will post prototype code on github
		2. Add backlog task to Review TDW-II changes based on recent profile updates.
	h. Topic (	6: Query / Retrieve
	i.	Koua reviewed the Q/R Use Case and Clinical Impact Statement (ihe-ro.org), and a draft of
220		the Query Retrieve Profile.
	ii.	Options that can be supported with the DICOM C-FIND model were discussed. Three levels
		were considered:
		1. A basic Q/R mode supports DICOM required query keys and provides instance UIDs
		for retrieval of objects
225		2. An enhanced hierarchical query model that includes RT-specific attributes, e.g., RT
		Plan Label, Name, and Referenced Structure Sets
		3. A full relational query that can return related object references.
	iii.	Instance-level C-MOVE is needed with three Actors:
		1. C-MOVE SCU
230		2. C-MOVE SCP/C-STORE SCU
200		3. C-STORE SCP
	iv	Support for matching (M) and return (R) keys should be specified in the DICOM Content
	1	requirements.
235	[Lunch break 9/27, 12:3	30-1:30pm]
	L	
	v.	The Study Root query keys for Study, Series, Patient, modules were reviewed. A
		preliminary set of required attributes to be returned was discussed.
	i. Topic :	5: ROI Template
240		Walter presented a draft of a DICOM ROI Template Supplement
		Discussion included textual and programmatic instructions for segmentation
		A reference to online protocol text was added.
		Some clarification of scope information is needed before presentation to DICOM WG-06.
	V.	
245		2: Connectathon Update
210	<b>U</b>	This year – Walter presented a preliminary report of Connectation results
		Things to improve / change
	11.	1. Concern was expressed that two Connectations per year may not be sustainable.
		<ol> <li>Concern was expressed that two connectations per year may not be sustainable.</li> <li>Long time until re-test if there is only one annual test event.</li> </ol>
250		<ol> <li>Good attendance is more important than frequency of test events.</li> </ol>
230		<ol> <li>4. Informal testing does have value, but may not be worth the cost.</li> </ol>
		<ol> <li>Management needs to commit resources to testing.</li> </ol>
		<ul><li>6. Diminished connectivity issues – victim of own success?</li></ul>
		<ol> <li>7. Value of Test Results? Not just about "gold stars".</li> </ol>
		7. Faire of results: not just about gold stars.

iii. Mandate for Vendors to Support Profiles1. Re-commitment is needed from high-level vendor management.

<ul> <li>260</li> <li>k. Topic 2: Connectathon Update (cont.) / DCOM / Prep for discussion with PC att <ol> <li>Need to engage top level of ASTRO/IHE-RO Oversight to approach ver re-emphasize importance of IHE-RO participation.</li> <li>Need to get vendor acknowledgement that they need to show up for the Clearer expectation of participation in IHE-RO membership agreement? Connectathon participants?</li> <li>Build IHE-RO Brand as <i>the</i> platform for interoperability in radiation on iv. Other discussion points</li> <li>Corporate benefit of participation. Cost of <i>not</i> participating?</li> <li>Align Connectathon site as sponsored, held at clinical site?</li> <li>Re-consider fee model for IHE-RO? A-la-carte vs. all-you-can-4. What happens with test tools development if funding changes?</li> <li>Who pays for independent resources? (Judges, etc.)</li> <li>Still need a Connectathon is.</li> </ol> </li> <li>275 275 76 776 70 70 70 70 70 70 70 70 70 70 70 70 70</li></ul>	
<ul> <li>i. Need to engage top level of ASTRO/IHE-RO Oversight to approach ver re-emphasize importance of IHE-RO participation.</li> <li>ii. Need to get vendor acknowledgement that they need to show up for the Clearer expectation of participation in IHE-RO membership agreement? Connectathon participants?</li> <li>iii. Build IHE-RO Brand as <i>the</i> platform for interoperability in radiation on iv. Other discussion points         <ol> <li>Corporate benefit of participation. Cost of <i>not</i> participating?</li> <li>Align Connectathon site as sponsored, held at clinical site?</li> <li>Re-consider fee model for IHE-RO? A-la-carte vs. all-you-can-4. What happens with test tools development if funding changes?</li> <li>Who pays for independent resources? (Judges, etc.)</li> <li>Still need a Connectathon</li> <li>Pro-active process to decide which profiles will be tested?</li> <li>v. Priorities:                 <ol> <li>High-level management-to-management communication that pa RO Connectathon is not optional.</li> <li>Make IHE-RO participation more visible and valuable to the ve</li> <li>Build primary ASTRO branding for IHE-RO. ("Connectathon F booth). Improve publicity for IHE-RO.</li> <li>Changes in BRTO-II with respect to BRTO:</li></ol></li></ol></li></ul>	
<ul> <li>ii. Need to get vendor acknowledgement that they need to show up for the Clearer expectation of participation in IHE-RO membership agreement? Connectathon participants?</li> <li>iii. Build IHE-RO Brand as <i>the</i> platform for interoperability in radiation on iv. Other discussion points <ol> <li>Corporate benefit of participation. Cost of <i>not</i> participating?</li> <li>Align Connectathon site as sponsored, held at clinical site?</li> <li>Re-consider fee model for IHE-RO? A-la-carte vs. all-you-can- 4. What happens with test tools development if funding changes?</li> <li>Who pays for independent resources? (Judges, etc.)</li> <li>Still need a Connectathon</li> </ol> </li> <li>275 <ol> <li>Pro-active process to decide which profiles will be tested?</li> <li>Priorities: <ol> <li>High-level management-to-management communication that pa RO Connectathon is not optional.</li> <li>Make IHE-RO participation more visible and valuable to the ve</li> <li>Build primary ASTRO branding for IHE-RO. ("Connectathon F booth). Improve publicity for IHE-RO.</li> </ol> </li> <li>285 <ol> <li>Copic 9: BRTO-II / Segmentation Profile – Sven reviewed a draft of the BRTO- i. Changes in BRTO-II with respect to BRTO: <ol> <li>CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ol> </li> </ol></li></ol></li></ul>	
<ul> <li>265 Clearer expectation of participation in IHE-RO membership agreement? Connectathon participants?</li> <li>iii. Build IHE-RO Brand as <i>the</i> platform for interoperability in radiation on iv. Other discussion points <ol> <li>Corporate benefit of participation. Cost of <i>not</i> participating?</li> <li>Align Connectathon site as sponsored, held at clinical site?</li> <li>Re-consider fee model for IHE-RO? A-la-carte vs. all-you-can- 4. What happens with test tools development if funding changes?</li> <li>Who pays for independent resources? (Judges, etc.)</li> <li>Still need a Connectathon</li> </ol> </li> <li>275 7. Pro-active process to decide which profiles will be tested?</li> <li>v. Priorities: <ol> <li>High-level management-to-management communication that pa RO Connectathon is not optional.</li> <li>Make IHE-RO participation more visible and valuable to the ve 3. Build primary ASTRO branding for IHE-RO. ("Connectathon F booth). Improve publicity for IHE-RO.</li> </ol> </li> <li>285 1. Topic 9: BRTO-II / Segmentation Profile – Sven reviewed a draft of the BRTO- i. Changes in BRTO-II with respect to BRTO:</li> <li>CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ul>	
<ul> <li>Connectathon participants?</li> <li>iii. Build IHE-RO Brand as <i>the</i> platform for interoperability in radiation on iv. Other discussion points <ol> <li>Corporate benefit of participation. Cost of <i>not</i> participating?</li> <li>Align Connectathon site as sponsored, held at clinical site?</li> <li>Re-consider fee model for IHE-RO? A-la-carte vs. all-you-can-4. What happens with test tools development if funding changes?</li> <li>Who pays for independent resources? (Judges, etc.)</li> <li>Still need a Connectathon</li> </ol> </li> <li>275 <ol> <li>Pro-active process to decide which profiles will be tested?</li> <li>Priorities: <ol> <li>High-level management-to-management communication that pa RO Connectathon is not optional.</li> <li>Make IHE-RO participation more visible and valuable to the ve</li> <li>Build primary ASTRO branding for IHE-RO. ("Connectathon F booth). Improve publicity for IHE-RO.</li> </ol> </li> <li>1. Topic 9: BRTO-II / Segmentation Profile – Sven reviewed a draft of the BRTO-i. CP1395 (Extent RT Structure Set ROI Color)</li> <li>CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ol></li></ul>	
<ul> <li>iii. Build IHE-RO Brand as <i>the</i> platform for interoperability in radiation on iv. Other discussion points <ol> <li>Corporate benefit of participation. Cost of <i>not</i> participating?</li> <li>Align Connectathon site as sponsored, held at clinical site?</li> <li>Re-consider fee model for IHE-RO? A-la-carte vs. all-you-can-4. What happens with test tools development if funding changes?</li> <li>Who pays for independent resources? (Judges, etc.)</li> <li>Still need a Connectathon</li> </ol> </li> <li>275 <ol> <li>Pro-active process to decide which profiles will be tested?</li> <li>Priorities: <ol> <li>High-level management-to-management communication that pa RO Connectathon is not optional.</li> <li>Make IHE-RO participation more visible and valuable to the ve</li> </ol> </li> <li>280 <ol> <li>Topic 9: BRTO-II / Segmentation Profile – Sven reviewed a draft of the BRTO-i. CP1395 (Extent RT Structure Set ROI Color)</li> <li>CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ol> </li> </ol></li></ul>	Publish
<ul> <li>iv. Other discussion points <ol> <li>Corporate benefit of participation. Cost of <i>not</i> participating?</li> <li>Align Connectathon site as sponsored, held at clinical site?</li> <li>Re-consider fee model for IHE-RO? A-la-carte vs. all-you-can-4. What happens with test tools development if funding changes?</li> <li>Who pays for independent resources? (Judges, etc.)</li> <li>Still need a Connectathon</li> </ol> </li> <li>275 <ol> <li>Pro-active process to decide which profiles will be tested?</li> <li>Priorities: <ol> <li>High-level management-to-management communication that pa RO Connectathon is not optional.</li> <li>Make IHE-RO participation more visible and valuable to the ve</li> </ol> </li> <li>280 <ol> <li>Build primary ASTRO branding for IHE-RO. ("Connectathon F booth). Improve publicity for IHE-RO.</li> </ol> </li> <li>285 <ol> <li>CP1314 (Add Category Code Sequence to RT Structure Set)</li> </ol> </li> </ol></li></ul>	1
<ol> <li>Corporate benefit of participation. Cost of <i>not</i> participating?</li> <li>Align Connectathon site as sponsored, held at clinical site?</li> <li>Re-consider fee model for IHE-RO? A-la-carte vs. all-you-can- 4. What happens with test tools development if funding changes?</li> <li>Who pays for independent resources? (Judges, etc.)</li> <li>Still need a Connectathon</li> <li>Pro-active process to decide which profiles will be tested?</li> <li>v. Priorities:         <ol> <li>High-level management-to-management communication that pa RO Connectathon is not optional.</li> <li>Make IHE-RO participation more visible and valuable to the ve</li> <li>Build primary ASTRO branding for IHE-RO. ("Connectathon F booth). Improve publicity for IHE-RO.</li> </ol> </li> <li>Topic 9: BRTO-II / Segmentation Profile – Sven reviewed a draft of the BRTO- i. Changes in BRTO-II with respect to BRTO:         <ol> <li>CP1395 (Extent RT Structure Set ROI Color)</li> <li>CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ol> </li> </ol>	cology
<ul> <li>270</li> <li>2. Align Connectathon site as sponsored, held at clinical site?</li> <li>3. Re-consider fee model for IHE-RO? A-la-carte vs. all-you-can- 4. What happens with test tools development if funding changes?</li> <li>5. Who pays for independent resources? (Judges, etc.)</li> <li>6. Still need a Connectathon</li> <li>275</li> <li>7. Pro-active process to decide which profiles will be tested?</li> <li>v. Priorities: <ol> <li>High-level management-to-management communication that pa RO Connectathon is not optional.</li> <li>2. Make IHE-RO participation more visible and valuable to the ve</li> <li>3. Build primary ASTRO branding for IHE-RO. ("Connectathon F booth). Improve publicity for IHE-RO.</li> </ol> </li> <li>285</li> <li>285</li> <li>CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ul>	
<ol> <li>Re-consider fee model for IHE-RO? A-la-carte vs. all-you-can- 4. What happens with test tools development if funding changes?</li> <li>Who pays for independent resources? (Judges, etc.)</li> <li>Still need a Connectathon</li> <li>Pro-active process to decide which profiles will be tested?</li> <li>v. Priorities:         <ol> <li>High-level management-to-management communication that pa RO Connectathon is not optional.</li> <li>Make IHE-RO participation more visible and valuable to the ve</li> <li>Build primary ASTRO branding for IHE-RO. ("Connectathon F booth). Improve publicity for IHE-RO.</li> </ol> </li> <li>Topic 9: BRTO-II / Segmentation Profile – Sven reviewed a draft of the BRTO-i. Changes in BRTO-II with respect to BRTO:         <ol> <li>CP1395 (Extent RT Structure Set ROI Color)</li> <li>CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ol> </li> </ol>	
<ul> <li>4. What happens with test tools development if funding changes?</li> <li>5. Who pays for independent resources? (Judges, etc.)</li> <li>6. Still need a Connectathon</li> <li>7. Pro-active process to decide which profiles will be tested?</li> <li>v. Priorities: <ol> <li>High-level management-to-management communication that pa RO Connectathon is not optional.</li> <li>Make IHE-RO participation more visible and valuable to the ve</li> <li>Build primary ASTRO branding for IHE-RO. ("Connectathon F booth). Improve publicity for IHE-RO.</li> </ol> </li> <li>1. Topic 9: BRTO-II / Segmentation Profile – Sven reviewed a draft of the BRTO-i. Changes in BRTO-II with respect to BRTO: <ol> <li>CP1395 (Extent RT Structure Set ROI Color)</li> <li>CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ol> </li> </ul>	4 (9
<ul> <li>5. Who pays for independent resources? (Judges, etc.)</li> <li>6. Still need a Connectathon</li> <li>7. Pro-active process to decide which profiles will be tested?</li> <li>v. Priorities: <ol> <li>High-level management-to-management communication that pa RO Connectathon is not optional.</li> <li>Make IHE-RO participation more visible and valuable to the ve</li> <li>Build primary ASTRO branding for IHE-RO. ("Connectathon F booth). Improve publicity for IHE-RO.</li> </ol> </li> <li>1. Topic 9: BRTO-II / Segmentation Profile – Sven reviewed a draft of the BRTO-i. Changes in BRTO-II with respect to BRTO: <ol> <li>CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ol> </li> </ul>	-test?
<ul> <li>6. Still need a Connectathon</li> <li>7. Pro-active process to decide which profiles will be tested?</li> <li>v. Priorities: <ol> <li>High-level management-to-management communication that par RO Connectathon is not optional.</li> <li>Make IHE-RO participation more visible and valuable to the ve</li> <li>Build primary ASTRO branding for IHE-RO. ("Connectathon F booth). Improve publicity for IHE-RO.</li> </ol> </li> <li>1. Topic 9: BRTO-II / Segmentation Profile – Sven reviewed a draft of the BRTO-i. Changes in BRTO-II with respect to BRTO: <ol> <li>CP1395 (Extent RT Structure Set ROI Color)</li> <li>CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ol> </li> </ul>	
<ul> <li>275</li> <li>7. Pro-active process to decide which profiles will be tested?</li> <li>v. Priorities: <ol> <li>High-level management-to-management communication that par RO Connectathon is not optional.</li> <li>Make IHE-RO participation more visible and valuable to the versional.</li> <li>Build primary ASTRO branding for IHE-RO. ("Connectathon F booth). Improve publicity for IHE-RO.</li> </ol> </li> <li>1. Topic 9: BRTO-II / Segmentation Profile – Sven reviewed a draft of the BRTO-i. Changes in BRTO-II with respect to BRTO: <ol> <li>CP1395 (Extent RT Structure Set ROI Color)</li> <li>CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ol> </li> </ul>	
<ul> <li>v. Priorities:         <ol> <li>High-level management-to-management communication that par RO Connectathon is not optional.</li> <li>Make IHE-RO participation more visible and valuable to the ve</li> <li>Build primary ASTRO branding for IHE-RO. ("Connectathon F booth). Improve publicity for IHE-RO.</li> </ol> </li> <li>1. Topic 9: BRTO-II / Segmentation Profile – Sven reviewed a draft of the BRTO-i. Changes in BRTO-II with respect to BRTO:             <ol> <li>CP1395 (Extent RT Structure Set ROI Color)</li> <li>CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ol> </li> </ul>	
<ol> <li>High-level management-to-management communication that par RO Connectathon is not optional.</li> <li>Make IHE-RO participation more visible and valuable to the ve</li> <li>Build primary ASTRO branding for IHE-RO. ("Connectathon F booth). Improve publicity for IHE-RO.</li> <li>Topic 9: BRTO-II / Segmentation Profile – Sven reviewed a draft of the BRTO- i. Changes in BRTO-II with respect to BRTO:         <ol> <li>CP1395 (Extent RT Structure Set ROI Color)</li> <li>CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ol> </li> </ol>	
<ul> <li>RO Connectathon is not optional.</li> <li>2. Make IHE-RO participation more visible and valuable to the ve</li> <li>280</li> <li>3. Build primary ASTRO branding for IHE-RO. ("Connectathon F booth). Improve publicity for IHE-RO.</li> <li>1. Topic 9: BRTO-II / Segmentation Profile – Sven reviewed a draft of the BRTO-i. Changes in BRTO-II with respect to BRTO: <ul> <li>1. CP1395 (Extent RT Structure Set ROI Color)</li> <li>2. CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ul> </li> </ul>	
<ul> <li>280</li> <li>3. Build primary ASTRO branding for IHE-RO. ("Connectathon F booth). Improve publicity for IHE-RO.</li> <li>1. Topic 9: BRTO-II / Segmentation Profile – Sven reviewed a draft of the BRTO-i. Changes in BRTO-II with respect to BRTO:</li> <li>285</li> <li>1. CP1395 (Extent RT Structure Set ROI Color)</li> <li>2. CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ul>	irticipation in the IHE-
<ul> <li>booth). Improve publicity for IHE-RO.</li> <li>1. Topic 9: BRTO-II / Segmentation Profile – Sven reviewed a draft of the BRTO- i. Changes in BRTO-II with respect to BRTO:         <ol> <li>CP1395 (Extent RT Structure Set ROI Color)</li> <li>CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ol> </li> </ul>	ndor community.
<ol> <li>Topic 9: BRTO-II / Segmentation Profile – Sven reviewed a draft of the BRTO- i. Changes in BRTO-II with respect to BRTO:         <ol> <li>CP1395 (Extent RT Structure Set ROI Color)</li> <li>CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ol> </li> </ol>	Participant" Badge in
<ul> <li>i. Changes in BRTO-II with respect to BRTO:</li> <li>285</li> <li>1. CP1395 (Extent RT Structure Set ROI Color)</li> <li>2. CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ul>	
<ol> <li>CP1395 (Extent RT Structure Set ROI Color)</li> <li>CP 1314 (Add Category Code Sequence to RT Structure Set)</li> </ol>	II Profile
2. CP 1314 (Add Category Code Sequence to RT Structure Set)	
3. CP1398 (Add FOR Module to RT Structure Set)	
4. Optional support for hi-res ROI contours in RT Structure Set	
5. Require equidistantly-spaced dose grid points	
2906. Define tolerance of 0.01 mm	
7. Eliminate Geometric Planner Actor	
8. Require Software Version to General Equiment Model	
9. Require only Instance Creation Date (R+), Instance Creation Time	me (R+), and Specific
Character Set (O+*, see section) in SOP Common	
ii. ACTION 150901: Sven to complete incorporation of changes and updat	te draft for review at
Oct 2015 TC meeting.	
m. Topic 7: Consistent Dose for External Beam (CDEB) Review – Chris reviewed	a draft of the CDEB
Profile	
i. The CDEB Profile draft specifies requirements for the content of RT Pla	an and RT Beams
300 Treatment Record IODs transferred among the following Actors:	
1. CDEB Plan Producer	
2. TDD (CDEB Plan Consumer, CDEB Beams Record Producer)	
3. CDEB Dose Tracker (Plan Consumer, Beams Record Consumer	
ii. Requirements for RT Plan content have already been included in the TD	
305 iii. The content requirements on RT Plan and RT Beams Treatment Record	can be incorporated
directly into the TDW-II Profile.	
iv. ACTION 150902: Chris to revise the profile, removing references to Ac	
Supplement to insert content requirements into the Technical Framewor	k.
n. Topic 8: Review and approval of minutes from last meetings.	

255

	<ul><li>i. Minutes from the July 29, 2015 TC teleconference were approved without objection.</li><li>ii. Minutes from the August 26, 2015 TC teleconference were approved without objection.</li></ul>
315	<ul> <li>Topic 11: BrachyTherapy and ION IHE-RO efforts – Uli reviewed a draft of the "Brachytherapy Workflow (BWF)" Profile document (v.1.2) and "Treatment Planning – Ion Plan Content" (TPPC- ION) Profile (v 1.1).</li> </ul>
320	<ul> <li>i. There is some variation in the process flow in Brachytherapy treatment planning and delivery.</li> <li>ii. Emphasis is on the content of the RT Brachy Application Setup Module for HDR, PDR, LDR with applicator, and LDR without applicator.</li> <li>iii. The primary author for the Brachy profile is Milena Donato</li> <li>iv. A primary author is needed for the Ion Profile.</li> </ul>
325	[Lunch break 9/29, 12:30-1:30pm]
525	<ul> <li>p. Topic 13.5: Discuss next steps: RO-HIS</li> <li>i. Proposal to outline use case(s) for a profile. What is the scope?</li> <li>ii. Variations is process flow: scheduling in HIS vs. scheduling in TMS</li> </ul>
330	<ul> <li>iii. A Clinical Impact Statement already exists for Consistent Patient ID in Rad Onc (CPRO)</li> <li>iv. ACTION 150903: Scott to draft Clinical Impact Statements for the following Use Cases: (1) Scheduling Consistency, (2) Billing, and (3) Treatment Summary</li> <li>v. ACTION 150904: Rickard to draft a white paper to survey existing profiles and data standards for cross-over with RO-HIS Use Case from the IHE-RO PC.</li> </ul>
335	q. Topic 14.5: 3:00 - Call with Dr. Koontz, Adam Earwicker re: PC Use Cases
	r. Topic 14.7: Review TC presentation for ASTRO meeting
340	[Adjourn for the day 9/29 at 5:10 pm] [Resume on 9/29 at 8:50am]
	s. Topic 14.8: Connectathon next year? i. Possible changes
345	<ol> <li>Single Connectathon per year – in the Fall</li> <li>Concurrent "Connectivity Workshop" for other vendors?</li> </ol>
	<ul> <li>3. Short post-Connectathon meeting on Saturday (8am-Noon)</li> <li>4. Use second Connectathon slot for Profile Development</li> <li>ii. Consensus</li> <li>1. Plan for one Connectathon for 2016</li> </ul>
350	<ol> <li>Plan for one Connectathon for 2016</li> <li>Short (1/2 day) TC meeting after Connectathon</li> <li>Timing: Fall 2016, after ASTRO - Week of Oct 17<sup>th</sup> or Oct 24<sup>th</sup></li> <li>Location: US         <ul> <li>a. Philips, Madison, WI</li> </ul> </li> </ol>
355	b. Sun Nuclear, Melbourne, FL
555	<ul> <li>t. Other TC Meetings in 2016 <ol> <li>Jan/Feb Face-to-Face – Jan 25-29, 2016, Location TBD, (Melbourne, FL?)</li> <li>April/May Face-to-Face – May 9-13, 2016, Europe? (need host)</li> <li>After ASTRO – Wed, Sep 28 - Sat (AM), Oct 1, 2016, Boston, MA</li> </ol> </li> </ul>
360	
	<ul> <li>u. Topic 12: TDW-II Update</li> <li>i. Uli reviewed the TDW-II Supplement document.</li> <li>ii. This document uses the DICOM Content section (Vol III, Chap. 7) of the Technical Framework. Uli is maintaining this material – any suggested changes should be sent to him.</li> </ul>

365		iii. Consistent Dose for External Beam (CDEB) constraints for RT Beams Treatment Record are now incorporated into the TDW-II Profile. Single target tracking is mandatory. Multiple-
		target dose tracking is an Option for the TDD Actor.
		iv. <b>DECISION:</b> It is expected that dose for a partial (interrupted) treatment delivery is reported as
270		a fraction of the total dose proportional to the Meterset delivered.
370		v. Add RT Ion Plan Storage SOP Class support for OST on C-MOVE Request.
		vi. Content requirements for RT Plan: add "All Plan IODs shall conform to 7.3.2.2.3 RT Plan IOD for Consistent Dose Tracking."
		<i>vii</i> . Display requirements of 7.3.2.1.2 RT Plan IOD for Photon External Beam in Delivery State
		are not applicable in this transaction.
375	V	iii. Add content requirements for Beams Delivery Instruction.
		ix. Add RT Ion Beams Treatment Record Storage as a SOP class.
		x. Display requirements of dose from RT (Ion) Beams Treatment Record "present accumulated dose values to the user allowing to observe progress of treatments."
		xi. <b>DECISION</b> : the TDW-II Profile with changes from 9/30/2015 (version 12) was voted to
380		Public Comment without objection.
	:	<ul> <li>ACTION 150905: Uli to send version 12 of TDW-II Profile to Chris to be published for Public Comment.</li> </ul>
		view of Minutes and Action Items.
385	w. Pre	liminary Agenda for ASTRO Meeting
	III. Future Meet	ings
	a. IH	E-RO Meetings
		i. IHE-RO Meeting at ASTRO – Oct 21-24, 2015 in San Antonio, TX
390		ii. IHE-RO TC Meeting – Jan 25-29, 2016 (tentative), Location TBD (Melbourne?)
	b. Otl	her meetings through 2015
		i. RSNA Nov 29-Dec 4, 2015, Chicago, IL
		ii. ICCR June 27-30, 2016, London
395		iii. AAPM Jul 31-Aug 4, 2016, Washington
		iv. ASTRO Sep 25-28, 2016
		v. DICOM WG-7 Nov 2-6, 2015 in Washington, DC
		vi. DICOM WG-7 May / June 2016
		vii. DICOM WG-7 Aug 4-6, 2016 (after AAPM) in Washington, DC
400		iii. DICOM WG-7 Oct 31-Nov 4, 2016
		ix. DICOM WG-6 Nov 9-13, 2015, Washington, DC
		x. DICOM WG-6 Jan 18-22, 2016, Washington, DC
		xi. DICOM WG-6 Mar 7-11, 2016, Washington, DC
		tii. DICOM WG-6 June 10, 2016, Europe
405		iii. DICOM WG-6 Sep 12-16, 2016, Washington, DC
-		iv. DICOM WG-6 Nov 7-11, 2016, Washington, DC

IV. Adjournment at 11:20am EDT 9/30/15

410

415	Appendix: Us	e Cases in Development – Discussion with B. Koontz and A. Earwicker
	a.	<b>Treatment Delivery Device Integration</b> – covered by TDPC, TDIC, treatment delivery workflow
420		<ul><li>profiles.</li><li>i. What additional common workflows in the RT clinic are not covered by the existing Profiles?</li></ul>
		<ul><li>E.g., patient QA.</li><li>ii. Treatment Record consistent content is not yet addressed (Dose Tracking is to be addressed in CDEB Profile)</li></ul>
425	h	iii. Patient QA? Radiation Oncology Workflow Exchange with HIS (ROWE) – Scope? CPRO is a start, but
723	0.	addresses only patient identification. See IHE-ITI Patient Information Reconciliation (PIR) Profile. A working relationship with HIS manufacturer(s) and HL7 expertise is needed.
		i. More detailed information regarding the scope of this Use Case is needed.
430		<ul><li>ii. Survey of existing standards and profiles</li><li>iii. CIS for RO-HIS Use Cases</li></ul>
150		iv. Participation with IHE-HL7 workgroup? IHE-ITI workgroup?
		v. Neil Martin (BWH) may be a resource
	с.	<b>User Case Anonymization</b> – See IHE-ITI Anonymization Handbook. The IHE-RAD TF1 Teaching
435		<ul><li>File and Clinical Trials Export (TCE) Profile may be good a starting point.</li><li>i. To what extent is this an interoperability problem?</li></ul>
433		ii. What is the deliverable? RO-TCE Profile? RO-specific anonymization handbook?
		iii. Are there Rad Onc specific considerations?
		iv. What are the legal and regulatory requirements? HIPAA? IRB?
	d.	<b>Brachytherapy</b> – DICOM standard (1 <sup>st</sup> gen) is in place – a Brachytherapy Profile is in development in
440		DICOM Brachy Sub-group
		i. A workflow profile is needed for brachytherapy treatment delivery.
	e.	Authentication / Authorization – See IHE-ITI Enterprise User Authentication (EUA) and Cross-
		Enterprise User Assertion (XUA) Profiles as a starting point.
445		<ul><li>i. Is any additional profile development required?</li><li>ii. Any Rad Onc specific issues?</li></ul>
445		iii. Role of IHE-RO in making vendors aware of profiles in other domains? What drives
		implementation? User awareness/demand?
	f.	Survivorship Care Plan – communicate ASTRO Survivorship Care Plan Template to TMS. Gather,
		store, communicate patient care information from TMS and EHR for follow-up care of RT.
450		i. What is the workflow to gather these data?
		ii. Where are the data stored?
		iii. How are they to be communicated?
	~	iv. Where are they to be reviewed?
455	g.	<b>Off-line Review 3rd Party Imaging</b> – Image content is addressed by TPIC, TDIC. Workflow is addressed by IPDW, DPDW.
-55		i. Existing imaging applications do not completely and consistently implement DICOM.
		ii. Content Profiles are in Public Comment
	h.	
		(require consistent handling of patient geometry and labeling).
460		